Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206334 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
A Phase 1 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02206334 is a Phase 1 study that has completed, run by NRG Oncology. The registered enrollment target is 42 participants.
The verdict
NCT02206334, a Phase 1 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of cancer in the body while minimizing radiation exposure of surrounding normal tissue.
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-08 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206334
The ClinicalTrials.gov registry entry for NCT02206334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT02206334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02206334 about?
NCT02206334 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer". This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused...
What is the current status of trial NCT02206334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-08. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT02206334?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT02206334?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.